Decision to list urology and continence medical devices
We are pleased to announce the approval of listing agreements with Culpan Distributors for urology and continence products and Reynard Health Supplies Limited for continence products in Part III of Section H of the Pharmaceutical Schedule from 1 November
In summary this will result in:
- Culpan and Reynard’s medical devices being listed in Part III or Section H of the Pharmaceutical Schedule from 1 November 2019 under national agreements that all DHBs may purchase under.
- DHBs being able to continue to purchase other suppliers’ brands of urology and continence products as the agreement is not for sole supply.
Any changes to the original proposal?
This decision was subject to a consultation letter dated 29 August 2019
Consultation feedback received in relation to the agreement with Culpan resulted in an amendment to the terms for urology products. Two urology products were removed from the Culpan agreement.
No changes were made to the Reynard proposal as a result of consultation feedback.
Who we think will be most interested
- Suppliers and Wholesalers
- DHB Staff
- clinical staff in a range of inpatient, outpatient and community settings where continence products are used
- procurement and supply chain personnel
Detail about this decision
The RFP requested proposals for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
After completing the RFP evaluation process and consulting on the provisional agreements with Culpan and Reynard PHARMAC has decided to list Culpan’s urology and continence products and Reynard’s continence products in Part III of Section H of the Pharmaceutical Schedule from 1 November 2019.
DHBs can continue to choose which urology and continence products they purchase, including those from other suppliers. DHBs that purchase urology and continence products from Culpan and continence products from Reynard must do so under the terms and conditions, including pricing, in the agreements, from 1 November 2019.
The agreements include terms and conditions for training and education to be provided by Culpan and Reynard on the appropriate use of its products, which is to be provided at times as agreed with individual DHBs.
Our response to what you told us
We appreciate the time people took to respond to this consultation.
All consultation responses received by 19 September 2019 were considered in their entirety in making the decision to approve these agreements.
A summary of the main themes raised in feedback and our responses to the feedback are set out below:
|
Theme |
Comment |
|---|---|
|
Reynard and Culpan |
|
|
Advised no technical or resource impacts are expected as a result of the proposal. |
Noted. |
|
Reynard |
|
|
A DHB advised that the minimum shelf life on delivery was too short. |
PHARMAC staff note that this is a minimum shelf life on delivery and takes into account the shelf life from date of manufacture. Products may be delivered with a longer shelf life. |
|
Culpan |
|
|
Feedback received from DHBs on the feasibility of implementing the terms for urology products. |
The agreement was amended to take into account this feedback and reflect terms that DHBs would be able to implement. |
If you have any questions about this decision, you can email us at enquiry@pharmac.govt.nz; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.